CEO Chaim Lebovits was paid $750,303 in fiscal year 2024, up 0.0% from fiscal year 2023 (SEC filing 0001104659-25-049785 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$750,303 Chaim Lebovits total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get BRAINSTORM CELL THERAPEUTICS INC.'s free Compensation Brief as a PDF, emailed to you now — plus a few short notes on the deeper BCLI reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Chaim Lebovits | $387,500 | $121,654 | $100,715 | — | — | — | $140,434 | $750,303 |
| Chief Executive Officer & President | ||||||||
| Ibrahim Dagher | 294,000 | 103,750 | 71,855 | — | — | — | 28,973 | 498,578 |
| Executive Vice President, Chief Medical Officer | ||||||||
| Stacy Lindborg | 125,947 | 100,000 | 79,839 | — | — | — | 40,589 | 346,375 |
| Former Co-Chief Executive Officer | ||||||||
| Uri Yablonka | 151,390 | 0 | 36,111 | — | — | — | 78,637 | 266,138 |
| Executive Vice President, Chief Business Officer, Secretary and Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Chaim Lebovits | $750,303 | $750,303 | — | +0 |
| Ibrahim Dagher | 498,578 | — | — | — |
| Stacy Lindborg | 346,375 | 346,375 | — | +0 |
| Uri Yablonka | 266,138 | 266,138 | — | +0 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ibrahim Dagher | Option | 3,666 | 25.95 | — |
| Chaim Lebovits | RSU | 20,347 | — | 46,188 |
| Lindborg | RSU | 16,129 | — | 36,613 |
| Ibrahim Dagher | RSU | 14,516 | — | 32,951 |
| Yablonka | RSU | 7,295 | — | 16,560 |
| Chaim Lebovits | RSU | 1,559 | — | 3,540 |
| Chaim Lebovits | RSU | 1,039 | — | 2,360 |
| Chaim Lebovits | RSU | 520 | — | 1,180 |
The Company's compensation philosophy is not explicitly detailed in a dedicated section, but the GNC Committee is responsible for reviewing and approving compensation programs to ensure they do not create risks reasonably likely to have a material adverse effect on the company. The Committee annually reviews and approves corporate goals relevant to CEO compensation and evaluates performance against these goals to set compensation levels.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Menghisteab BairuIndependent · Audit | $60,000 | $0 | $0 | — | — | $60,000 |
| Dr. Anthony PolverinoIndependent · GNC | 0 | 0 | 0 | — | — | 0 |
| Mr. Nir NaorIndependent · Audit (Chair) · GNC | 0 | 0 | 0 | — | — | 0 |
| Prof. Jacob FrenkelIndependent · Board Chair | 0 | 0 | 0 | — | — | 0 |
| Dr. Irit ArbelIndependent · GNC (Chair) · Audit | 0 | 0 | 0 | — | — | 0 |
| Mr. Uri YablonkaEmployee director | — | — | — | — | — | 0 |
| Dr. Stacy LindborgIndependent · Newly elected | — | — | — | — | — | — |
| Annual cash retainer | $0 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $60,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $60,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BRAINSTORM CELL THERAPEUTICS INC. | 2024 | Chaim Lebovits | $387,500 | $100,715 | — | — | $750,303 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Chaim Lebovits | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Executive Compensation”. As printed: 750,303. Filing ↗ |
| 2 | Section 01, Ibrahim Dagher | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Executive Compensation”. As printed: 498,578. Filing ↗ |
| 3 | Section 01, Stacy Lindborg | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Executive Compensation”. As printed: 346,375. Filing ↗ |
| 4 | Section 01, Uri Yablonka | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Executive Compensation”. As printed: 266,138. Filing ↗ |
| 5 | Section 08, Dr. Menghisteab Bairu | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 60,000. Filing ↗machine: span 458416–458422 |
| 6 | Section 08, Dr. Anthony Polverino | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 7 | Section 08, Mr. Nir Naor | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 8 | Section 08, Prof. Jacob Frenkel | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 08, Dr. Irit Arbel | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 08, Mr. Uri Yablonka | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 08, Dr. Stacy Lindborg | DEF 14A | 2025-05-16 | 0001104659-25-049785 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 60,000 + equity 0 + all other 0 = 60,000, summed across the director compensation table rows.machine: formula: Σ = 60,000 |
| 14 | BRAINSTORM CELL THERAPEUTICS INC. (subject), Section 10b CEO total | DEF 14A | 2025-05-16 | 0001104659-25-049785 | CEO total compensation as printed in BRAINSTORM CELL THERAPEUTICS INC.'s own proxy. As printed: 750,303. Filing ↗ |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat